Recent briefings covering the 30-day period through mid-August 2026 recorded no material discrete corporate events, new regulatory disclosures, or new corporate announcements for AbbVie Inc. Successive briefs dated through 2026-08-15 each noted the absence of new filings beyond routine administrative activity. No new product approvals, litigation developments, or strategic transactions were flagged during the period [Brief - 2026-08-15].
AbbVie's trailing twelve-month financials as of 30 June 2026 show revenue of $64.39 billion, representing year-over-year growth of 10.16%. Net income for the same period stood at $6.31 billion, yielding a net margin of 9.80%. Gross margin was recorded at 65.73% and operating margin at 26.20%. Earnings per share grew 290.38% year-over-year on a TTM basis. The company held $6.57 billion in cash against total debt of $64.50 billion, and the trailing P/E ratio was 72.03 [SEC 10-Q - ABBV - 2026-06-30].
Insider activity in September 2026 comprised two transactions, both disposals, with a combined net value of approximately -$8.18 million [SEC Form 4 - ABBV - 2026-09]. On the institutional side, several notable position changes were reported in the most recent 13F filings. Citadel added approximately 76% to its ABBV position, Millennium increased its holding by roughly 35%, and AQR Capital more than doubled its position with a 127% addition. Conversely, Bridgewater reduced its position by approximately 61% [SEC 13F - Citadel - Q2 2026; SEC 13F - Millennium - Q2 2026; SEC 13F - AQR Capital - Q2 2026; SEC 13F - Bridgewater - Q2 2026].
The prevailing macroeconomic backdrop features the 10-year US Treasury yield at 4.83% and the 2-year yield at 4.39%, producing a normal yield curve spread of approximately 44 basis points [FRED DGS10; FRED DGS2]. This rate environment is relevant context for evaluating AbbVie's total debt load of $64.50 billion relative to its operating cash generation.
This report was generated in response to material institutional position changes across multiple large hedge fund filers, as reflected in the most recently available 13F disclosures.